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ABSTRACT
Background and Objectives: Endothelin (ET)-1, a potent endothelium-derived vasoconstrictor peptide, has a potential 
pathophysiologic role in pulmonary hypertension. Bosentan, a dual ET receptor (ETA/ETB) antagonist, is efficacious in treat-
ment of pulmonary hypertension. The objectives of this study were to investigate the expression of ET-1 and ET receptor A 
(ERA) genes and to evaluate the effect of bosentan in monocrotaline (MCT)-induced pulmonary hypertension. Materials 
and Methods: Four-week-old male Sprague-Dawley rats were treated as follows: control (n=36), subcutaneous (sc) injection 
of saline; MCT (n=36), sc injection of MCT (60 mg/kg); and bosentan (n=36), sc injection of MCT (60 mg/kg) plus 25 mg/kg/
day bosentan orally. Results: Serum ET-1 concentrations in the MCT group were higher than the control group on day 28 
and 42. Quantitative analysis of peripheral pulmonary arteries revealed that the increase in medial wall thickness after MCT 
injection was significantly attenuated in the bosentan group on day 28 and 42. In addition, the increase in the number of in-
tra-acinar muscular arteries after MCT injection was reduced by bosentan on day 14, 28 and 42. The levels of ET-1 and ERA 
gene expression were significantly increased in the MCT group compared with control group on day 5, and bosentan decreased 
the expression of ET-1 on day 5. Conclusion: ET-1 contributes to the progression of cardiopulmonary pathology in rats with 
MCT-induced pulmonary hypertension. Administration of bosentan reduced ET-1 gene expression in MCT-induced pulmo-
nary hypertension in rats. (Korean Circ J 2010;40:459-464)
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Introduction
Pulmonary arterial hypertension progressively increases 
pulmonary vascular resistance, which leads to right ventricu-
lar failure and is often fatal.
1) The molecular mechanisms by 
which endothelial vasomediators contribute to pulmonary 
hypertension have not been fully elucidated. Endothelin-1 (ET- 
1), a potent endothelium-derived vasoconstrictor peptide, was 
identified in 1988.
2) Circulating ET-1 levels are elevated in hu-
mans who have primary and secondary pulmonary hyperten-
sion
3)4) as is local pulmonary ET-1 expression,
5) which suggests 
that this peptide may contribute to the pathogenic process. In 
addition, increased plasma ET-1 levels correlate with the se-
verity of pulmonary hypertension in chronic congestive he-
art failure.
6) ET-1 has several properties suggesting its poten-
tial pathophysiologic role in pulmonary hypertension.
7) First, 
ET-1 contracts isolated pulmonary vessels and increases pul-
monary vascular resistance. Second, ET-1 has a mitogenic ef-
fect on vascular smooth muscle cells and fibroblasts, consis-
tent with a role in vascular remodeling, a prominent finding in 
pulmonary hypertension. 
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receptor subtypes.
8) ETA receptors are localized on vascular 
smooth muscle cells and mediate the constrictive
9) and prolife-
rative effects,
10) and ETB receptors are localized on the vascular 
endothelium and mediate vasorelaxation
11) by increasing the 
formation of prostacyclin and nitric oxide,
12) as well as the cl-
earance of circulating ET-1.
13)14) The ETB receptors are present 
on the smooth muscle cells as well, where they also mediate 
vasoconstriction.
15) 
Monocrotaline (MCT) injures the endothelium of pulmo-
nary arteries and induces progressive pulmonary hyperten-
sion in rats after a single subcutaneous (sc) injection.
16) Bo-
sentan is efficacious in experimental and clinical pulmonary 
hypertension.
6)17-21) Bosentan improves hemodynamics, in-
creases exercise capacity, and decreases the rate of clinical 
worsening in patients with World Health Organization Class 
III or IV pulmonary arterial hypertension.
18) However, the ef-
fect of bosentan on alterations in the endothelial system and 
subsequent pulmonary medial hypertrophy, pulmonary hy-
pertension, and right ventricular hypertrophy has not been 
established in this model.
The objectives of this study were to investigate the effect of 
bosentan on ET-1 and ET receptor A (ERA) gene expression in 
MCT-induced pulmonary hypertension. 
Materials and Methods
Experimental animals
Four-week-old male Sprague-Dawley rats, weighing appro-
ximately 250 g, were used for this study. All rats were housed 
in climate-controlled conditions with a 12 hours light : 12 
hours dark cycle, and had free access to chow and water.
Pulmonary hypertension was induced by the sc injection of 
60 mg/kg MCT (Sigma Chemicals, St. Louis, MO, USA) dis-
solved in 0.5 N HCl solution. The rats were grouped as fol-
lows: control (n=36), sc injection of saline (0.1 mL/kg); MCT 
(n=36), sc injection of MCT; bosentan (n=36), sc injection of 
MCT plus 25 mg/kg/day bosentan (Actelion Pharmaceuticals 
Ltd., Allschwil, Switzerland) by gavage during all experimen-
tal days. The rats were sacrificed after 1, 5, 7, 14, 28, and 42 
days. Lung tissues were removed and immediately frozen at 
-70°C for enzyme analysis, post-fixed in 10% formalin, and 
routinely processed for paraffin embedding. All protocols 
were approved by the Institutional Review of Board (IRB) of 
the School of Medicine of Ewha Womans University.
Endothelin-1 concentration in serum 
Serum was collected to determine ET-1 concentrations. The 
serum ET-1 concentration was measured using a human ET-1 
immunoassay kit (QuantiGlo; R&D Systems, Minneapolis, 
MN, USA) by a sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for ET-1 was pre-coated and im-
mobilized onto a microplate, followed by samples with ET-1. 
After washing, an enzyme-linked monoclonal antibody spe-
cific for ET-1 was added to the wells. Following a wash to re-
move any unbound antibody-enzyme reagent, an enhanced 
luminol/peroxide substrate solution was added to the wells 
and light was produced in proportion to the amount of ET-1 
bound in the initial step. A microplate luminometer was used 
to measure the intensity of the light emitted. 
Morphometric analysis of pulmonary arteries
Hematoxylin and eosin staining was performed using 3 μm 
tissue sections fixed in formalin and embedded in paraffin for 
examination under a light microscope. The measurements of 
the external diameter (D) and medial thickness on either side 
(M1 and M2) were made along the shortest D. Measurements 
were made at random on 30 muscular arteries, ranging in size 
from 25-100 μM in D, per lung section. For each artery, the 
medial wall thickness was expressed as follows: % wall thi-
ckness={(M1+M2)/D}×100. In addition, the number of mus-
cular intra-acinar arteries per field (×200) was counted. A total 
of 20 fields were examined in each rat for this analysis. Micro-
scopic examination and photography were performed with a 
Nikon E600 microscope with a JVC digital camera attached to 
a phototube. The Image-pro Plus 6.0 program was used for 
morphometric analysis.
Ribonucleic acid extraction and complementary 
deoxyribonucleic acid synthesis
Total ribonucleic acid (RNA) was extracted by using TRIzol 
Reagent
TM (Invitrogen, Carlsbad, CA, USA), according to the 
Trizol method protocol, and resuspended in diethyl pyrocar-
bonate water. Final RNA was spectrophotometrically deter-
mined at 260/280 nm. Quality was assessed as the absence 
of smear of 18S and 28S bands using a Bio analyzer 2100 (Ag-
ilent). RNA samples were stored at -70°C until used. Comple-
mentary deoxyribonucleic acids (cDNAs) were synthesized by 
1 μg of total RNA according to the manufacturer’s protocol 
(High Capacity RNA-to-cDNA kit, Applied Biosystems, USA).
Gene expression analysis by real time reverse 
transcription-polymerase chain reaction
Real-time quantitative polymerase-chain reaction (PCR) was 
performed in triplicate in 384-well plates using the ABI Prism 
7900 Sequence Detection System (PE Applied Biosystems) 
and white 384-well plates (ABgene, Hamburg, Germany) to in-
tensify fluorescent signals. The system uses a thermal cycler 
and a laser that is directed via fiber optics to sample wells. The 
fluorescence emission from each sample was collected by a 
charge-coupled device-camera and the data were analyzed 
using the Sequence Detection System software (SDS version 
2.0, PE Applied Biosystems). Reaction mixtures contained 10 
pmol/μL of each primer and 2X SYBR Green PCR Master Mix 
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DNA-Polymerase in an optimized buffer, the dNTP mix (with 
dUTP additive), the SYBRs Green I fluorescent dye, and ROX 
dye as a passive reference. Each of the PCR plates included 
serial dilutions (1, 1/2 and 1/4) of cDNA for generating rela-
tive standard curves. 
The resulting first-strand of cDNA was normalized by the 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene. 
The specific primers for rat ET-1 were 5’-TCTCGGAGAG 
CAGAGACACA-3’ (forward) and 5’-TGGACTTTGGAG 
TTTCTCCCT-3’ (reverse). The specific primers for ERA were 
5’-CACAGGCTTCAGTGTGCATT-3’ (forward) and 5’- 
CAACACAGGCCCTTAGCTTC-3’ (reverse). All cDNAs 
were amplified using the same conditions: 50°C for 2 minutes 
and 95°C for 10 minutes followed by 40 cycles of 95°C for 30 S 
and 60°C for 30 S, then extension at 72°C for 30 S. Melting 
curve analysis of products was routinely performed after am-
plification using an incremental temperature increase from 
60°C to 95°C at a ramp rate of 0.21°C/sec. We then converted 
real-time PCR cycle numbers to gene amounts (ng). 
Statistical analysis 
Results were expressed as the mean±standard deviation. 
An unpaired two-tailed t-test and Mann-Whitney test were 
used, and p<0.05 was considered statistically significant. Sta-
tistical Package for the Social Sciences (SPSS) 12.0 for win-
dows (SPSS Inc., Chicago, IL, USA) was used for all statistical 
analyses.
Results
Endothelin-1 concentration in serum 
MCT significantly increased serum ET-1 concentrations 
from day 28 {0.97±0.54 pg/mL (MCT) vs. 0.28±0.15 pg/mL 
(control), p<0.05}. Bosentan increased mean serum ET-1 
concentration 5-fold over MCT on day 1 {1.92±0.35 pg/mL 
(bosentan) vs. 0.36±0.08 pg/mL (MCT), p<0.05}, and 7 {1.19± 
0.40 pg/mL (bosentan) vs. 0.20±0.11 pg/mL (MCT), p<0.05}, 
and by 2-fold on day 14 {1.21±0.34 pg/mL (bosentan) vs. 0.57± 
0.36 pg/mL (MCT), p<0.05} (Table 1).  
Histologic study
The basic pulmonary architecture was similar in each 
group. The predominant changes in pulmonary vasculature 
included the development of medial thickening in the pul-
monary arterioles in the MCT group compared with control 
and bosentan group (Fig. 1). Quantitative analysis of the pe-
ripheral pulmonary arteries demonstrated that bosentan at-
tenuated the increase wall thickness after MCT injection on 
day 28 and 42 (Fig. 2). Bosentan also attenuated the increased 
number of intra-acinar muscular arteries induced by MCT 
on day 1, 14, 28 (Fig. 3).
Expression of Endothelin-1 mesenger ribonucleic 
acid and Endothelin receptor A mesenger ribonucleic 
acid in rat lung tissue 
The reverse transcription-polymerase-chain reaction (RT-
PCR) products from the transcripts of ET-1, ERA, and GAP-
DH were 156 bp, 118 bp and 89 bp (Fig. 4). MCT increased 
the expression of ET-1 (4.19±1.84 vs. 1±0.20) and ERA (3.35 
±1.26 vs. 1±0.34) genes compared with control on day 5 (p< 
0.05). Bosentan attenuated this increase in ET-1 on day 5 (Fig. 
5) (Table 2). MCT also increased pulmonary ERA mRNA on 
Table 1. Changes in endothelin-1 concentrations in rat serum (pg/mL)
Days  Control group MCT group Bosentan group
01 0.34±0.06 0.36±0.08 1.92±0.35*
†
07 0.23±0.11 0.20±0.11 1.19±0.40*
†
14 0.20±0.06 0.57±0.36 1.21±0.34*
†
28 0.28±0.15   0.97±0.54* 2.52±3.04*
42 0.16±0.04   1.02±0.24* 3.35±3.43
*p<0.05 vs. control group, †p<0.05 vs. MCT group. MCT: monocro-
taline
B   C  
Fig. 1. Hematoxylin-eosin staining of lung tissue. Monocrotaline (MCT) treatment thickened the muscular layer of the pulmonary arteriole at 42 
days (B) compared to controls (A), and bosentan blocked this effect (C). Magnification: ×400.
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day 5 (3.35±1.26 vs. 1±0.34, p<0.05), but bosentan did not af-
fect this expression. There was no significant difference in the 
expression of pulmonary ERA mRNA among the three groups 
(Fig. 6) (Table 3). 
Discussion
We confirmed MCT-induced pulmonary hypertension by 
pathologic findings and gene expression changes. The predo-
minant changes in the pulmonary vasculature included an 
increased number of intra-acinar muscular arteries from 1 day 
and the developmental changes of medial thickening in pul-
monary arteriole in MCT group from 1 week. The ratio of right 
ventricle to left ventricle+septum increased after 2 weeks.
22) 
MCT also induced a significant rise in pulmonary blood pres-
sure and apparent RVH.
19)23)24) MCT also increased serum 
ET-1 concentrations from day 28, as well as ET1 and ERA 
gene expression on day 5.  
The effect of endothelin receptor antagonists on MCT- in-
duced pulmonary hypertension is controversial. Continuous 
infusion of BQ-123
22)23) and orally active LU 135252,
25) a selec-
tive ETA receptor antagonist, inhibited right ventricular hy-
pertrophy in MCT rats. LU 135252, however, did not modi-
fy MCT-induced medial hypertrophy of pulmonary arteries. 
Fig. 4. RT-PCR products for endothelin-1 and endothelin receptor 
A in rat lung tissue on day 5. The RT-PCR products from the tran-
scripts of ET-1, endotelin receptor A and GAPDH were 156 bp, 118 
bp and 89 bp. RT-PCR: reverse transcription-polymerase chain 
reaction, ET-1: Endothelin-1, GAPDH: glyceraldehyde 3-phosphate 
dehydrogenase.
242 bp
190 bp
147bp
110 bp
GAPDH
89
Edn 1
156
Ednra
118
67 bp
7
6
5
4
3
2
1
0
E
x
p
r
e
s
s
i
o
n
 
c
h
a
n
g
e
Fig. 5. Gene expression of endothelin-1 after bosentan treatment.
MCT increased ET-1 gene expression compared with controls on 
day 5 (p<0.05), and bosentan blocked this increase (p<0.05). *p<0.05 
vs. control group, †p<0.05 vs. MCT group. MCT: monocrotaline, ET-
1: Endothelin-1.
1 day 7 days 14 days 28 days 5 days
*
†
Control
Monocrotaline
Treatment
*p<0.05 vs. control
†p<0.05 vs. monocrotaline
Table 2. Expression of endothelin-1 mRNA in lungs
Day  Control group MCT group Bosentan group
01 1.00±0.25 1.85±1.44 1.48±0.37
05 1.00±0.20 4.19±1.84* 1.78±1.25†
07 1.00±0.29 0.73±0.31 0.33±0.12
14 1.00±0.51 0.26±0.17 0.18±0.03
28 1.00±0.50 0.61±0.28 0.36±0.30
*p<0.05 vs. control group, †p<0.05 vs. MCT group. MCT: monocro-
taline. mRNA: messenger ribonucleic acid
16
14
12
10
8
6
4
2
0
Time (days)
N
u
m
b
e
r
 
o
f
 
m
u
s
c
u
l
a
r
i
z
e
d
 
a
r
t
e
r
i
e
s
Fig. 3. Bosentan reduced the MCT-induced increase in the number 
of muscularized peripheral pulmonary arteries on days 1, 14, 28, and 
42 (p<0.05 in each group). MCT: monocrotaline.
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Fig. 2. Peripheral pulmonary artery thickness. MCT increased % wall 
thickness, and bosentan blocked this effect on days 28 (p<0.05) 
and 42 (p<0.05). MCT: monocrotaline.
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Here, bosentan reduced ET-1 gene expression on day 5 and 
the number of intra-acinar muscular arteries in the pulmonary 
arterioles from day 14. Bosentan also reduced medial thick-
ness and RVH after 28 days, indicating a reduction in pulmo-
nary hypertension, as shown previously.
22) 
We showed here for the first time that bosentan inhibited 
pulmonary vascular remodeling in MCT rats. Increased pul-
monary artery thickness contributes to MCT-induced pul-
monary hypertension and sustained irreversible increases in pul-
monary vascular resistance.
23) Bosentan prevented arterial 
medial thickening in the MCT rats, suggesting that endoge-
nous ET-1 participates in the thickening of pulmonary ves-
sels. Similarly, bosentan blocked the MCT-induced increase 
in the number of muscular intra-acinar arteries, potentially 
indicating neo-muscularization of non-muscular pulmonary 
arteries in the distal area to respiratory bronchioles. Similarly, 
sildenafil changed the muscularization of peripheral pulmo-
nary arteries, with 40-50 intra-acinar arteries categorized as 
muscular, partially muscular, or non-muscular, although the 
definition of artery only included small vessels.
26) Bosentan 
inhibited the MCT-induced increase in the number of mus-
cular intra-acinar arteries.  
MCT increased serum ET-1 concentrations on day 28. Mi-
yauchi et al.
23) reported that MCT increased plasma ET-1 lev-
els on day 10, potentially due to differences in animal species, 
age, and hemodynamic characteristics. Serum ET-1 remain-
ed elevated at week 4, but lung ET-1 gene expression was only 
elevated on day 5. Elevated serum ET-1 levels may result from 
increased production by the heart
23)27) and kidney,
23) as well as 
pulmonary inflammation, because the lung, kidney, and liver 
are the main sites for the removal of circulating ET-1.
28)
Early increases in serum ET-1 putatively results from ET-1 
release from storage compartments or from ET receptors. In 
contrast, later ET-1 elevations could result from extra-pulmo-
nary ET-1 production, such as from ventricular myocytes re-
sponding to pressure overload. In severe pulmonary hyper-
tension, ET-1 can be influenced by vascular surface area and 
receptor-mediated ET-1 clearance as well as changes in ET-1 
receptor density and binding. In healthy human subjects, plas-
ma ET-1 levels increased a maximum of two-fold within 24 
hours after administration of oral bosentan.
29) Loffler et al.
30) 
found that the administration of Ro 46-2005, a bosentan ana-
logue, increased early circulating ET-1 levels in rat plasma, 
suggesting that ET-1 levels are not a result of de novo synthesis. 
In another MCT model, chronic intravenous infusion of a 
specific ETA antagonist (BQ 123) reduced pulmonary hyper-
tension,
23) whereas sc administration of another such antago-
nist (FR 139317) prevented RVH without affecting pulmona-
ry hypertension.
31) Bosentan (300 mg/kg/day) significantly 
attenuated the increase in the main pulmonary arterial pres-
sure and RVH, and reduced plasma catecholamines and mor-
tality.
19) Different potencies and pharmacokinetic profiles 
may explain these various findings. 
MCT increased the expression of ET1 and ERA genes on 
day 5, and bosentan blocked this increase. Lung ET-1 produc-
tion increases in rats with pulmonary hypertension 4 weeks 
after aorta banding.
32) Thus, changes in lung ET-1 production 
are not consistent in animal models of pulmonary hyperten-
sion. Severe inflammation of the lung parenchyma or severe 
damage of the pulmonary endothelial cells caused by MCT 
may increase ET-1 mRNA in the lung. Prepro ET-1 mRNA 
expression increases in the hearts of the MCT rats at the se-
vere pulmonary hypertensive stage,
23) potentially due to he-
art overload. Our data suggest that extra-pulmonary ET-1 
production or trans-pulmonary ET-1 clearance might chan-
ge ET-1 concentrations in serum.
In conclusion, bosentan reduced the development of MCT-
induced pulmonary hypertension and subsequent RVH and 
vascular remodeling. These results suggest that ET-1 may 
play a role in RVH and remodeling in MCT-induced pulmo-
nary hypertension. Increased ET-1 gene expression was an 
earlier marker than other pathologic findings or serum ET-1. 
Further studies are in progress to determine the effects of 
bosentan on other gene expressions in MCT-induced pulmo-
nary hypertension in rats
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Fig. 6. Gene expression of endothelin-receptor A after bosentan 
treatment MCT increased ERA mRNA compared with controls on 
day 5 (p<0.05). *p<0.05 vs. control group. MCT: monocrotaline, ERA: 
endothelin receptor A.
1 day 7 days 14 days 28 days 5 days
* Control
Monocrotaline
Treatment
*p<0.05 vs. control
Table 3. Expression of endothelin receptor A mRNA in lungs
Day  Control group MCT group Bosentan group
01 1.00±0.32 1.84±1.46 2.00±0.94
05 1.00±0.34   3.35±1.26*     2.96±4.05*
†
07 1.00±0.49 0.92±0.61 0.19±0.05
14 1.00±0.26 0.42±0.26 0.21±0.02
28 1.00±0.71 2.03±0.80 0.91±0.42
*p<0.05 vs. control group, †p<0.05 vs. MCT group. MCT: monocro-
taline. mRNA: messenger ribonucleic acid464   Gene Expression of Endothelin in Pulmonary Hypertension After Bosentan Treatment
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